Dr. Leonardo Ferreira is an Assistant Professor of Microbiology and Immunology at the Medical University of South Carolina. The Ferreira lab uses CARs and other engineered immune receptors to dissect how specificity, affinity, and signaling modulate the function of different T cells subsets in tolerance and immunity. He talks about how CAR Tregs could prevent transplant rejection and treat Type 1 diabetes. He also discusses mixing and matching immune cells, the freedom to pursue multiple ideas in academia, and science outreach in Bolivia
Read More
Dr. Mark Shlomchik is a UPMC Endowed Distinguished Professor and Chair of the Department of Immunology at the University of Pittsburgh. He is also a Founder and Chief Scientific Officer of BlueSphere Bio, a company working to create individualized T cell therapies for the treatment of cancer. Dr. Shlomchik’s lab focuses on systemic autoimmune diseases, long-lived B cell immunity, and immunopathogenesis. He talks about the role of toll-like receptors in lupus, how his autoimmune disease research led to potential cancer therapies, and starting a biotech company with his brother.
Read More
Dr. Christopher Klebanoff is an Principal Investigator and Attending Physician at the Memorial Sloan Kettering Cancer Center. His research focuses on cell-based cancer immunotherapies, T cell receptors, and the therapeutic targeting of shared cancer neoantigens. Using single-cell sequencing, biophysical measurements of T cell receptor affinity, genetic engineering, and structural immunobiology, the Klebanoff lab aims to adapt adoptive T cell transfer for advanced solid tumors.
Read More
Dr. Carl June is the Richard W. Vague Professor in Immunology at the University of Pennsylvania, Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy. Dr. Philipp Rommel is a Postdoctoral Researcher in the June lab. Together, they are interested in lymphocyte biology, with a major translational focus on ex vivo T-cell engineering for cancer and HIV cell-based therapies.
Read More